Introduction to Proliferative Retinopathy and Vitrectomy

Proliferative retinopathy represents the most advanced stage of several retinal vascular diseases, most commonly diabetic retinopathy. When abnormal blood vessels grow on the surface of the retina or optic disc, they threaten vision through hemorrhage, traction, and retinal detachment. In these severe cases, vitrectomy surgery becomes a cornerstone intervention. This article examines the indications, surgical techniques, outcomes, and risks of vitrectomy for advanced proliferative retinopathy, with a focus on evidence-based management.

The global burden of diabetic retinopathy continues to rise, with an estimated 103 million people affected worldwide. Among these, approximately 17 million have proliferative diabetic retinopathy (PDR), making it a leading cause of preventable blindness in working-age adults. Vitrectomy, first developed in the 1970s, has evolved into a highly refined procedure that can restore and preserve vision even in the most challenging cases.

Pathophysiology of Proliferative Retinopathy

To understand why vitrectomy is necessary, one must first grasp the underlying disease process. Chronic hyperglycemia damages retinal capillaries through several mechanisms, including pericyte loss, endothelial dysfunction, and thickening of the basement membrane. These changes lead to capillary occlusion and retinal ischemia. In response, the retina releases vascular endothelial growth factor (VEGF) and other cytokines, stimulating the growth of new, fragile blood vessels.

These neovascular vessels lack the structural integrity of normal retinal vessels. They hemorrhage easily into the vitreous cavity, causing vitreous hemorrhage that can range from mild floaters to complete vision loss. Over time, fibrovascular proliferation develops, with scar tissue forming along the posterior hyaloid face. This fibrovascular tissue contracts, exerting traction on the retina and leading to tractional retinal detachment (TRD), the most vision-threatening complication.

Natural History Without Intervention

Without treatment, proliferative retinopathy follows a variable but often progressive course. The Diabetic Retinopathy Study (DRS) and Early Treatment Diabetic Retinopathy Study (ETDRS) established that high-risk characteristics—specifically, neovascularization of the disc greater than one-fourth disc area, or neovascularization elsewhere with accompanying vitreous hemorrhage—carry a 26% risk of severe vision loss within two years if left untreated. Even with panretinal photocoagulation (PRP), some patients progress to advanced disease requiring vitrectomy.

Indications for Vitrectomy in Advanced Proliferative Retinopathy

Vitrectomy is not the first-line treatment for most proliferative retinopathy. Instead, it is reserved for specific advanced situations where medical and laser therapies have failed or are inadequate. The primary indications include:

  • Non-clearing vitreous hemorrhage: When vitreous hemorrhage persists for more than 1–3 months despite observation and PRP, vitrectomy is indicated. Early vitrectomy (within 1–3 months) has been shown to improve visual outcomes compared to prolonged observation, especially in type 1 diabetes.
  • Tractional retinal detachment: Detachment involving or threatening the macula requires prompt surgical intervention. Even extramacular TRD may be considered for surgery if it progresses or causes symptoms.
  • Combined traction-rhegmatogenous retinal detachment: This complex scenario occurs when fibrovascular traction creates a retinal break, leading to both traction and subretinal fluid. Vitrectomy is essential to relieve traction and repair the break.
  • Severe fibrovascular proliferation: When active neovascularization with progressive fibrotic changes threatens retinal function despite maximal PRP and anti-VEGF therapy, vitrectomy may be considered prophylactically.
  • Neovascular glaucoma: In some cases, advanced proliferative retinopathy leads to angle closure from neovascularization. Vitrectomy with endolaser PRP can help control the disease.

Additionally, vitrectomy is increasingly performed earlier in the disease course due to improvements in surgical safety. The Diabetic Retinopathy Vitrectomy Study (DRVS) demonstrated that early vitrectomy (within six months of severe vitreous hemorrhage) resulted in better visual outcomes than deferral, particularly in patients with type 1 diabetes.

Preoperative Evaluation and Preparation

Before proceeding with vitrectomy, a comprehensive ophthalmic examination is essential. This includes measurement of best-corrected visual acuity, slit-lamp biomicroscopy, dilated fundus examination, and often B-scan ultrasonography when media opacities prevent direct visualization. Ultrasonography helps assess the extent of TRD, the presence of retinal breaks, and the status of the posterior hyaloid.

Systemic factors must also be optimized. Poor glycemic control (elevated HbA1c) increases the risk of postoperative inflammation, delayed healing, and recurrent neovascularization. Uncontrolled hypertension can exacerbate intraoperative hemorrhage. Renal function is important, as diabetic nephropathy affects anesthetic choices and fluid management. Preoperative anti-VEGF injections have become standard practice, administered 3–7 days before surgery to reduce intraoperative bleeding and facilitate surgical dissection.

Role of Anti-VEGF Therapy

Intravitreal bevacizumab (Avastin) or ranibizumab (Lucentis) given preoperatively has been shown to decrease intraoperative hemorrhage, shorten surgical time, and reduce the need for extensive endodiathermy. However, caution is needed: in eyes with extensive fibrovascular proliferation, anti-VEGF can accelerate fibrosis contraction, potentially converting a tractional detachment into a combined rhegmatogenous detachment. The risk is highest when injection is given too close to surgery (less than 3 days) or in eyes with pre-existing TRD. Most surgeons therefore wait 3–7 days and monitor for any change in traction before proceeding.

Vitrectomy Surgical Technique

Modern vitrectomy is performed using small-gauge (23-, 25-, or 27-gauge) sutureless systems, which offer faster recovery and less postoperative inflammation. The procedure typically involves the following steps:

  1. Sclerotomy creation: Three small incisions are made through the pars plana, 3.5–4.0 mm posterior to the limbus, to allow access for the vitreous cutter, light pipe, and infusion cannula.
  2. Core vitrectomy: The central vitreous is removed, creating space for subsequent maneuvers. Care is taken to avoid traction on the vitreous base.
  3. Posterior hyaloid elevation: The posterior hyaloid is separated from the retina, often using active suction with the cutter or a pick. In proliferative retinopathy, the hyaloid is often adherent to fibrovascular tissue and must be carefully dissected.
  4. Fibrovascular membrane segmentation and delamination: Using scissors, forceps, or a vitrector, the surgeon divides and removes the fibrovascular membranes. Horizontal and vertical cutting techniques are employed to relieve traction without causing iatrogenic breaks.
  5. Hemostasis: Bleeding from neovascular tissue is controlled with elevated infusion pressure, endodiathermy, or temporary tamponade with heavy liquids.
  6. Endolaser photocoagulation: After clearing hemorrhage and removing membranes, panretinal endolaser is applied to ischemic retina. This helps prevent recurrent neovascularization.
  7. Fluid-air exchange and tamponade: If retinal breaks are present, a gas or silicone oil tamponade is used to maintain retinal attachment. Air, sulfur hexafluoride (SF6), or perfluoropropane (C3F8) gas are common choices for straightforward cases; silicone oil is reserved for complex detachments or when long-term tamponade is needed.
  8. Closure: Sclerotomies are checked for leakage, and the eye is pressured with subconjunctival antibiotics and corticosteroids.

Innovations such as chandelier endoillumination, wide-angle viewing systems, and 3D visualization have greatly improved surgical precision. The use of perfluorocarbon liquids (PFCL) facilitates flattening of the retina and membrane removal in cases of combined TRD.

Key Intraoperative Challenges

Vitrectomy for proliferative retinopathy is among the most technically demanding procedures in ophthalmology. Common challenges include:

  • Iatrogenic retinal breaks: Overly aggressive traction on adherent membranes can create retinal holes. The incidence ranges from 5% to 15% in expert hands.
  • Uncontrolled hemorrhage: Despite preoperative anti-VEGF, bleeding may occur from severed vessels. Elevated infusion pressure (30–50 mmHg) and endodiathermy are used to achieve hemostasis.
  • Incomplete membrane removal: In very severe cases with diffuse fibrovascular proliferation, residual tissue may be left to avoid causing more damage.
  • Anesthesia considerations: Many patients have diabetes and may have autonomic neuropathy, cardiac comorbidities, or renal issues requiring careful monitoring.

Postoperative Care and Outcomes

After vitrectomy, patients are positioned according to the type of tamponade used. Gas-filled eyes require face-down positioning for retinal detachment repairs, but for vitrectomy alone without detachment, positioning is less critical. Topical antibiotics, corticosteroids, and cycloplegics are prescribed. Patients are advised to avoid air travel and high altitudes until gas absorbs (2–8 weeks depending on gas type).

Visual recovery varies. If vitrectomy was performed for vitreous hemorrhage in an otherwise healthy retina, vision can improve within days to weeks. For TRD involving the macula, recovery takes longer and may be incomplete. The DRVS reported that at two years after vitrectomy for severe vitreous hemorrhage, 50% of eyes achieved 20/40 vision or better, and 25% remained 20/200 or worse. Better preoperative visual acuity, shorter duration of disease, and younger age are favorable prognostic factors.

Long-Term Management

Vitrectomy does not cure the underlying diabetic retinopathy. Lifelong follow-up is required to monitor for recurrent neovascularization, macular edema, or cataract formation (the latter occurring in virtually all phakic eyes within a year). Anti-VEGF injections may be needed postoperatively for persistent neovascular activity. Patients must continue to manage systemic diabetes rigorously, as poor control leads to higher rates of recurrence.

Complications and Risks

While vitrectomy has become safer, complications remain possible. Cataract formation is nearly universal after vitrectomy in patients over 50, with progression often within 6–12 months. Cataract surgery can be performed later. Other risks include:

  • Postoperative vitreous hemorrhage: Occurs in 10–30% of cases, often from residual neovascularization or from sclerotomy sites. Most clear spontaneously within weeks, but some require repeat surgery.
  • Recurrent retinal detachment: Risk is higher in eyes with extensive TRD. Silicone oil tamponade reduces incidence but introduces its own issues (glaucoma, accelerated cataract, oil emulsification).
  • Endophthalmitis: Rare (0.02–0.05% in small-gauge surgery) but sight-threatening.
  • Macular edema: Can be present preoperatively or develop postoperatively. Treatment with topical NSAIDs or steroids may be needed.
  • Glaucoma: May be transient from gas expansion or persistent from silicone oil use.

The Role of Vitrectomy in the Anti-VEGF Era

Intravitreal anti-VEGF agents have revolutionized the management of diabetic retinopathy, reducing the incidence of progression to proliferative disease by up to 50% in large clinical trials. However, in advanced cases with established fibrosis and traction, anti-VEGF alone cannot resolve the mechanical component. Vitrectomy remains essential for addressing fibrovascular proliferation and retinal detachment.

The integration of anti-VEGF therapy as a surgical adjunct has been a major advance. Preoperative administration reduces intraoperative hemorrhage and surgical complexity. Postoperative use can treat residual neovascularization. However, the timing and frequency of anti-VEGF in the surgical setting require careful individualization, as some studies have reported an increased risk of tractional detachment when injected during active fibrosis.

Patient Selection and Shared Decision-Making

Given the complexity and potential risks of vitrectomy for proliferative retinopathy, careful patient selection is paramount. Not every patient with proliferative retinopathy requires surgery; many respond to PRP and anti-VEGF. Shared decision-making should include discussion of:

  • The natural history of the disease without surgery
  • The likelihood of visual improvement based on preoperative acuity and OCT findings
  • The risk of complications, including need for additional surgeries
  • The impact of systemic health on surgical outcomes
  • Postoperative expectations and the importance of follow-up

For patients with poor baseline vision (hand motion or worse) from a dense vitreous hemorrhage, vitrectomy offers a reasonable chance of significant improvement. For those with long-standing macula-off TRD, the prognosis is guarded, but surgery may still prevent phthisis and preserve some navigational vision.

Conclusion

Vitrectomy surgery remains a vital tool in the management of advanced proliferative retinopathy. By removing hemorrhage, relieving traction, and enabling effective laser photocoagulation, it can salvage vision in eyes that would otherwise progress to irreversible blindness. Advances in surgical technique, instrumentation, and adjunctive medical therapy have improved outcomes and reduced complications. Nevertheless, prevention through systemic diabetic control and timely application of PRP and anti-VEGF remains paramount. For patients with advanced disease, vitrectomy, when performed by an experienced surgeon, offers the best opportunity to preserve and restore sight.

For further reading, refer to the National Eye Institute’s overview of diabetic retinopathy, the American Society of Retina Specialists patient education page, and the 2021 Cochrane review on vitrectomy for diabetic retinopathy. Disclaimer: This article is for educational purposes and does not replace professional medical advice. Patients should consult their ophthalmologist for personalized recommendations.